KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

HUMAN ALBUMIN IMMUNO 5 %

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

5 %

 

GENERIC NAME:

HUMAN ALBUMIN

 

MANUFACTURER:

BEXTER

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

B

 

INDICATIONS:

Echocardiography, adjunct

 

SIDE EFFECTS:

Allergic reaction

chest pain

dyspnea

Dizziness

flushing of skin or sensation of warmth

headache

nausea and/or vomiting

Changes in taste

dryness of mouth

fatigue

pain at injection site

weakness

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

>> Cardiac shunt, right-to-left, bidirectional, or transient right-to-left

>> Heart defects, congenital

>> Hepatic function impairment, severe

Pulmonary disease, especially emphysema, pulmonary vasculitis, or history of pulmonary emboli

Respiratory distress syndrome

 

ADULT DOSE:

Cardiac imaging, ultrasound-Intravenous, 0.5 mL into a peripheral vein, administered at a rate not to exceed 1 mL per second . Note: The injection of the octafluoropropane-containing human albumin microspheres should be followed by a rapid flush with 0.9% sodium chloride injection or 5% dextrose injection . If contrast enhancement is not adequate after administration of a 0.5 mL-dose, a dose of 3 mL may be injected after 10 minutes . A third injection of 5 mL, 10 minutes after the second dose, may be used if needed for adequate contrast enhancement .

 

MAXIMUM ADULT DOSE:

 

PEDIATRIC DOSE:

Safety and efficacy have not been established .  

 

MAXIMUM PEDIATRIC DOSE:

 

ELDERLY DOSE:

Cardiac imaging, ultrasound-Intravenous, 0.5 mL into a peripheral vein, administered at a rate not to exceed 1 mL per second . Note: The injection of the octafluoropropane-containing human albumin microspheres should be followed by a rapid flush with 0.9% sodium chloride injection or 5% dextrose injection . If contrast enhancement is not adequate after administration of a 0.5 mL-dose, a dose of 3 mL may be injected after 10 minutes . A third injection of 5 mL, 10 minutes after the second dose, may be used if needed for adequate contrast enhancement .

 

 

PREVIOUS

  

NEXT